Elevated chromogranin A (CgA) serum levels in the patients with advanced pancreatic cancer

Archives of Gerontology and Geriatrics

Volumn 48, Issue 2, 2009, Pages 213-217

  Malaguarnera, Michele ^a   Cristaldi, Erika ^a   Cammalleri, Lisa ^a   Colonna, Valentina ^a   Lipari, Helga ^a   Capici, Alessandra ^a   Cavallaro, Andrea ^a   Beretta, Massimiliano ^a   Alessandria, Innocenza ^a   Luca, Salvatore ^a   Motta, Massimo ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

Carbohydrate antigen (CA19 9); Chromogranin A; Neuroendocrine components; Pancreatic cancer

Indexed keywords

CARBOHYDRATE ANTIGEN; CHROMOGRANIN A;

AGED; ARTICLE; CANCER PATIENT; CHRONIC PANCREATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MALE; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN DETERMINATION;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; CA-19-9 ANTIGEN; CASE-CONTROL STUDIES; CHROMOGRANIN A; FEMALE; HUMANS; MALE; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PANCREATITIS, CHRONIC; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

CHANDIPURA VIRUS;

EID: 58349102022     PISSN: 01674943     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.archger.2008.01.014     Document Type: Article

References (57)

1. Ahlgren J.D. Epidemiology and risk factors in pancreatic cancer. Semin. Oncol. 23 (1996) 241-250
2. Anderson R.J., and Lynch H.T. Familial risk for neuroendocrine tumours. Curr. Opin. Oncol. 5 (1993) 75-84
3. Bruns C., Lewis I., Briner U., Meno-tetang G., and Weckbecker G. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur. J. Endocrinol. 146 (2002) 707-716
4. Capella C., Heitz P.U., Höfler H., Solcia E., and Klöppel G. Revised classification of neuroendocrine tumours of the lung, pancreas and gut. Virchows Arch. 425 (1995) 547-560
5. Ceconi C., Ferrari R., Bachetti T., Opasich C., Volterrani M., Colombo B., Parrinello G., and Corti A. Chromogranin A in heart failure. A novel neurohumoral factor and a predictor for mortality. Eur. Heart J. 23 (2002) 967-974
6. Chen J., Baithun S.I., and Ramsay M.A. Histogenesis of pancreatic carcinomas: a study based on 248 cases. J. Pathol. 146 (1985) 65-76
7. Chen J., Baithun S.I., Pollock D.J., and Berry C.L. Argyrophilic and hormone immunoreactive cells in normal and hyperplastic pancreatic ducts and exocrine pancreatic carcinoma. Virchows Arch. A, Pathol. Anat. Histopathol. 413 (1988) 399-405
8. Compagno J., and Oertel J.E. Mucinous cystic neoplasms of the pancreas with overt and latent malignancy (cystadenocarcinoma and cystadenoma). A clinicopathologic study of 41 cases. Am. J. Clin. Pathol. 69 (1978) 573-580
9. Deftos L.J. Chromogranin A: its role in endocrine function and as an endocrine and neuroendocrine tumor marker. Endocr. Rev. 12 (1991) 181-187
10. Delesque N., Buscail L., Esteve J.P., Saint-Laurent N., Muller C., Weckbecker G., Bruns C., Vaysse N., and Susini C. SST2 somatostatin receptor expression reverses tumorigenicity of human pancreatic cancer cells. Cancer Res. 57 (1997) 956-962
11. Estensen M.E., Hognestad A., Syversen U., Squire I., Ng L., Kjekshus J., Dickstein K., and Omland T. Prognostic value of plasma chromogranin A levels in patients with complicated myocardial infarction. Am. Heart J. 152 (2006) e1-Le6
12. Glenn J., Steinberg W.M., Kurtzman S.H., Steinberg S.M., and Sindelar W.F. Evaluation of the utility of a radioimmunoassay for serum CA19-9 levels in patients before and after treatment of carcinoma of the pancreas. J. Clin. Oncol. 6 (1988) 462-468
13. Guillermet J., Saint-Laurent N., Rochaix P., Cuvillier O., Levade T., Schally A.V., Pradayrol L., Buscail L., Susini C., and Bousquet C. Somatostatin receptor subtype 2 sensitizes human pancreatic cancer cells to death ligand-induced apoptosis. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 155-160
14. Hauser H., Wolf G., Uranüs S., and Klimpfinger M. Neuroendocrine tumours in various organ system in a ten-year period. Eur. J. Surg. Oncol. 21 (1995) 297-300
15. Herlyn D., Herlyn M., Steplewski Z., and Koprowski H. Monoclonal antibodies in cell-mediated cytotoxicity against human melanoma and colorectal carcinoma. Eur. J. Immunol. 9 (1979) 657-659
16. Hsiao R.J., Seeger R.C., Yu A.L., and O'Connor D.T. Chromogranin A in children with neuroblastoma. J. Clin. Invest. 85 (1990) 1555-1559
17. Kimura N., Miura W., Noshiro T., Mizunashi K., Hanew K., Shimizu K., Watanabe T., Shibukawa S., Sohn H.E., Abe K., Miura Y., and Nagura H. Plasma chromogranin A in pheochromocytoma, primary hyperparathyroidism and pituitary adenoma in comparison with catecholamine, parathyroid hormone and pituitary hormones. Endocr. J. 44 (1997) 319-327
18. Kloppel G., Solcia E., Longnecker D.S., Capella C., and Sabin L.H. Histological typing of tumors of the exocrine pancreas. World Health Organization. International Histological Classification of Tumors. 2nd ed. (1996), Springer, Berlin, Heidelberg, New York pp. 15-21
19. Lamberts S.W., Van der Lely A.J., De Herder W.W., and Hofland L.J. Somatostatin analogs: future directions. Metabolism 45 (1996) 104-106
20. Li M., Fisher W.E., Kim H.J., Wang X., Brunicardi C.F., Chen C., and Yao Q. Somatostatin, somatostatin receptors, and pancreatic cancer. World J. Surg. 29 (2005) 293-296
21. Li-Ling J., and Irving M. Somatostatin and octreotide in the prevention of postoperative pancreatic complications and the treatment of enterocutaneous pancreatic fistulas: a systematic review of randomized controlled trials. Br. J. Surg. 88 (2001) 190-199
22. Metz-Boutigue M.H., Garcia-Sablone P., Hogue-Angeletti R., and Aunis D. Intracellular and extracellular processing of chromogranin A Determination of cleavage sites. Eur. J. Biochem. 217 (1993) 247-257
23. Metz-Boutigue M.H., Goumon Y., Lugardon K., Strub J.M., and Aunis D. Antibacterial peptides are present in chromaffin cell secretory granules. Cell. Mol. Neurobiol. 18 (1998) 249-266
24. Neary P.C., Redmond P.H., Houghton T., Watson G.R.K., and Bouchier-Hayes D. Carcinoid disease review of the literature. Dis. Colon Rectum 40 (1997) 349-362
25. Nobles F.R., Kwekkeboom D.J., Bouillon R., and Lamberts S.W. Chromogranin A: its clinical value as marker of neuroendocrine tumours. Eur. J. Clin. Invest. 28 (1998) 431-440
26. O'Connor D.T., and Frigon R.P. Chromogranin A, the major catecholamine storage vesicle soluble protein. J. Biol. Chem. 259 (1984) 3237-3247
27. O'Connor D.T., Pandlan M.R., Carlton E., Cervenka J.H., and Hslao R.J. Rapid radioimmunoassay of circulating chromogranin A: in vitro stability, exploration of the neuroendocrine character of neoplasia, and assessment of the effect of organ failure. Clin. Chem. 35 (1989) 1631-1637
28. Omland T., Dickstein K., and Syversen U. Association between plasma chromogranin A concentration and long-term mortality after myocardial infarction. Am. J. Med. 114 (2003) 25-30
29. Patel Y.C. Somatostatin and its receptor family. Front. Neuroendocrinol. 20 (1999) 157-198
30. Peters J., Jürgensen A., and Klöppel G. Ontogeny, differentiation and growth of the endocrine pancreas. Virchows Arch. 436 (2000) 527-538
31. Pleskow D.K., Berger H.J., Gyves J., Allen E., McLean A., and Podolsky D.K. Evaluation of a serologic marker, CA19-9, in the diagnosis of pancreatic cancer. Ann. Intern. Med. 110 (1989) 704-709
32. Pollak M.N., and Schally A.V. Mechanisms of antineoplastic action of somatostatin analogs. Proc. Soc. Exp. Biol. Med. 217 (1998) 143-152
33. Poon R.T., Lo S.H., Fong D., Tat Fan S., and Wong J. Prevention of pancreatic anastomotic leakage after pancreaticoduodenectomy. Am. J. Surg. 183 (2002) 42-52
34. Pour P.M., and Schmied B. The link between exocrine pancreatic cancer and the endocrine pancreas. Int. J. Pancreatol. 25 (1999) 77-87
35. Ranno S., Motta M., Rampello E., Risino C., Bennati E., and Malaguarnera M. The chromogranin-A (CgA) in prostate cancer. Arch. Gerontol. Geriatr. 43 (2006) 117-126
36. Reichlin S. Somatostatin. N. Engl. J. Med. 309 (1983) 1495-1501
37. Reisine T. Somatostatin receptors. Am. J. Physiol. 269 (1995) G813-G820
38. Reubi J.C. Somatostatin and other peptide receptors as tools for tumor diagnosis and treatment. Neuroendocrinology 80 (2004) 51-56
39. Reubi J.C., Laissue J., Krenning E., and Lamberts S.W. Somatostatin receptors in human cancer: incidence, characteristics, functional correlates and clinical implications. J. Steroid Biochem. Mol. Biol. 43 (1992) 27-35
40. Reubi J.C., Schaer J.C., Laissue J.A., and Waser B. Somatostatin receptors and their subtypes in human tumors and in peritumoral vessels. Metabolism 45 (1996) 39-41
41. Reubi J.C., Waser B., Schaer J.C., and Laissue J.A. Somatostatin receptor SST1-SST5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur. J. Nucl. Med. 28 (2001) 836-846
42. Rochaix P., Delesque N., Esteve J.P., Saint-Laurent N., Voight J.J., Vaysse N., Susini C., and Buscail L. Gene therapy for pancreatic carcinoma: local and distant antitumor effects after somatostatin receptor sst2 gene transfer. Hum. Gene Ther. 10 (1999) 995-1008
43. Rollhauser C., and Fleischer D.E. Upper gastrointestinal nonvariceal bleeding: a review covering the years 1996-97. Endoscopy 30 (1998) 114-125
44. Rosch T. The new TNM classification in gastroenterology 1997. Endoscopy 30 (1998) 643-649
45. Safi F., Roscher R., and Beger H.G. The clinical relevance of the tumor marker CA19-9 in the diagnosing and monitoring of pancreatic carcinoma. Bull. Cancer 77 (1990) 83-91
46. Safi F., Schlosser W., Kolb G., and Beger H.G. Diagnostic value of CA19-9 in patients with pancreatic cancer and nonspecific gastrointestinal symptoms. J. Gastrointest. Surg. 1 (1997) 106-112
47. Schaer J.C., Waser B., Mengod G., and Reubi J.C. Somatostatin receptor subtypes sst1, sst2, sst3 and sst5 expression in human pituitary, gastroentero-pancreatic and mammary tumors: comparison of mRNA analysis with receptor autoradiography. Int. J. Cancer 70 (1997) 530-537
48. Shojamanesh H., Gibril F., Louie A., Ojeaburu J.V., Bashir S., Abou-Saif A., and Jensen R.T. Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma. Cancer 94 (2002) 331-343
49. Spadaro A., Ajello A., Morace C., Zirilli A., D'arrigo G., Luigiano C., Martino F., Bene A., Migliorato D., Turiano S., Ferrau O., and Freni M.A. Serum chromogranin-A in hepatocellular carcinoma: diagnostic utility and limits. World J. Gastroenterol. 11 (2005) 1987-1990
50. Stridsberg M., and Husebye E.S. Chromogranin A and chromogranin B are sensitive circulating markers for phaeochromocytoma. Eur. J. Endocrinol. 136 (1997) 67-73
51. Suda K., and Hashimoto K. Argyrophil cells in the exocrine pancreas. Acta Pathol. Jpn. 29 (1979) 413-419
52. Syversen U., Jacobsen M.B., O'Connor D.T., Ronning K., and Waldum H.L. Immunoassays for measurement of chromogranin A and pancreastatin-like immunoreactivity in humans: correspondence in patients with neuroendocrine neoplasia. Neuropeptides 26 (1994) 201-206
53. Takiyyddin M.A., Cervenka J.H., Sullivan P.A., Pandian M.R., Parmer R.J., Barbosa J.A., and O'Connor D.T. Is physiologic sympathoadrenal catecholamine release exocytotic in humans?. Circulation 81 (1990) 185-195
54. Takiyyuddin M.A., Baron A.D., Cervenka J.H., Barbosa J.A., Neumann H.P., Parmer R.J., Sullivan P.A., and O'Connor D.T. Suppression of chromogranin-A release from neuroendocrine sources in man: pharmacological studies. J. Clin. Endocrinol. Metab. 72 (1991) 616-622
55. Tian F., Appert H.E., Myles J., and Howard J.M. Prognostic value of serum CA 19-9 levels in pancreatic adenocarcinoma. Ann. Surg. 215 (1992) 350-355
56. Wu J.T., Erickson A.J., Tsao K.C., Wu T.L., and Sun C.F. Elevated serum chromogranin A is detectable in patients with carcinomas at advanced disease stages. Ann. Clin. Lab. Sci. 30 (2000) 175-178
57. Zhang C.Y., Yokogoshi Y., Yoshimoto K., Fujinaka Y., Matsumoto K., and Saito S. Point mutation of the somatostatin receptor 2 gene in the human small cell lung cancer cell line COR-L103. Biochem. Biophys. Res. Commun. 210 (1995) 805-815